DecisionDx-MelanomaAugust 31, 2018
The staging of melanoma is important to predict risk of recurrence and guide surveillance and treatment. Current guidelines for staging include evaluating multiple features: tumor thickness, ulceration, regional lymph node status, and metastasis. Staging parameters provide some information of value in disease management, but there is wide variability in rates of metastasis, even for cancers of the same stage, limiting their predictive power. The development of additional tools that may provide more accurate information regarding staging and metastatic risk is, therefore, an area of active interest. One such tool is the DecisionDx-Melanoma test, a multigene expression assay that is designed to predict distant metastasis within 5 years of diagnosis in patients with stage I and II primary cutaneous melanoma.
If you have a Hayes login, click here to view the full report on the Knowledge Center.